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Copyright © 2011 JCBN 2011 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. Diabetes mellitus increases the risk of heart failure independently
of underlying coronary artery disease. It also causes skeletal muscle
dysfunction, which is responsible for reduced exercise capacity
commonly seen in heart failure. The underlying pathogenesis is
partially understood. Several factors may contribute to the
development of cardiac and skeletal muscle dysfunction in heart
failure and diabetes mellitus. Based on the findings in animal
models, this review discusses the role of oxidative stress that may
be involved in the development and progression of cardiac and
skeletal dysfunction associated with diabetes.
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Introduction Diabetes mellitus often leads to heart failure (HF), even in the
absence of any other risk factors such as coronary artery
disease or hypertension, suggesting that diabetes itself causes a
specific form of cardiomyopathic state.(1) Diabetes causes myo-
cardial structural remodeling characterized by myocyte hyper-
trophy, interstitial fibrosis, and apoptosis,(2) which increases
cardiac muscle stiffness and may contribute to diastolic dysfunc-
tion. Diastolic dysfunction has been regarded as a hemodynamic
hallmark seen in diabetes and ultimately contributes to the
development of HF.(3,4) Diabetes further worsens systolic dysfunc-
tion due to myocardial infarction (MI).(5–7) Previous clinical studies
have shown that patients with diabetes have a worse outcome after
MI than patients without diabetes despite similar left ventricular
(LV) ejection fractions and coronary patency rates.(8,9)
The features of diabetic heart disease have been well identified,
however, its pathogenesis and, in particular, the mechanisms
underlying myocardial remodeling have not been fully elucidated.
The excess production of reactive oxygen species (ROS), super-
oxide anion (O2￿−), H2O2, and hydroxyl radical (￿OH), resulting
in oxidative stress, is widely considered to be a cause of target
organ damage such as the heart, kidney, and skeletal muscle, in
diabetes.(10,11) Therefore, oxidative stress may contribute to the
development of cardiac and skeletal muscle dysfunction in diabetes.
Diabetic Heart
Diabetes mellitus causes both diastolic and systolic cardiac
dysfunction,(12) but an impairment of diastolic function usually
occurs before systolic dysfunction develops. The impairment of
diastolic function despite normal systolic function is thought to
result from an increased myocardial stiffness.
A growing body of evidence suggests that the production of
ROS is increased in the diabetic heart.(13) Specifically, ROS are
produced within the mitochondria of the diabetic heart.(14) The
first line of defense against ROS-mediated cardiac injury comprises
several antioxidant enzymes including superoxide dismutase
(SOD), catalase, and glutathione peroxidase (GSHPx). GSHPx is
a key antioxidant that catalyzes the reduction of H2O2 and
hydroperoxides. It not only scavenges H2O2 but also prevents the
formation of other more toxic radicals such as ￿OH. GSHPx
possesses a higher affinity for H2O2 than catalase. Furthermore,
it is present in relatively high amounts within the heart, especially
in the cytosolic and mitochondrial compartments.(15) These lines
of evidence imply the primary importance of GSHPx as a defense
mechanism within the heart. Moreover, GSHPx is expected to
exert greater protective effects against oxidative damage than
SOD because greater dismutation of O2￿− by SOD may result in an
increase of H2O2. Therefore, compared with SOD or catalase,
GSHPx is thought to be more effective in protecting cells, tissues,
and organs against oxidative damage.(16,17) In fact, the mice with
GSHPx gene overexpression were more resistant to myocardial
oxidative stress as well as remodeling and failure after MI.(18) In
the diabetic heart, the reduction of myocardial oxidative stress
by GSHPx overexpression was associated with the attenuation
of diastolic dysfunction, myocyte hypertrophy, and interstitial
fibrosis.(19) These findings are consistent with previous studies
demonstrating that ROS are involved in the structural alterations
of the extracellular matrix collagens.(20,21) The decline in myo-
cardial fibrosis by GSHPx overexpression may contribute to the
physiological improvement of diastolic properties.
There may be several factors whereby oxidative stress contributes
to myocardial remodeling in diabetes. First, oxidative stress is
involved in cardiac myocyte hypertrophy and apoptosis. A subtle
increase in ROS caused by partial inhibition of SOD results in
hypertrophy and apoptosis in isolated cardiac myocytes,(22) both of
which are thought to contribute to diabetic myocardial damage.
Specifically, the incidence of apoptosis is increased in the diabetic
heart,(23) which may cause loss of myocytes, compensatory hyper-
trophy of residual myocytes, and interstitial infibrosis.(24) Myocyte
necrosis may also be involved in the increased fibrosis from the
diabetic heart. Second, oxidative stress induces the activation of
matrix metalloproteinases (MMPs). We have demonstrated that
MMP-2 activation plays an important role in the pathophysiology
of cardiac remodeling.(25) Moreover, MMPs have been shown to
be activated by ROS in cardiac fibroblasts.(26) On the basis of
these findings, increased ROS may contribute to the activation
of MMP and thus to the development of interstitial fibrosis in
diabetes. Third, a possible role for growth factors in diabetes-
related end-organ complications is increasingly being recognized.
Transforming growth factor (TGF)-β and connective tissue
growth factor (CTGF) can induce the production of collagen and
fibronectin from cardiac fibroblasts and myocytes, and increased
expression of both factors contributes to the development and
progression of cardiac remodeling in diabetes.(27,28)
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Post MI Diabetic Heart
Previous clinical findings demonstrated that patients with
diabetes have a worse outcome after MI than that of patients
without diabetes despite similar coronary patency rate and base-
line LV ejection fraction.(8,9) Furthermore, in the clinical study of
patients with HF, diabetes reduced long-term survival independent
of the etiology of HF and baseline LV ejection fraction.(29) The
poor outomes in patients with diabetes have been shown to be
related with the progression of HF.(5–7)
Streptozotocin induces diabetes in rodents by chemical destruc-
tion of insulin-producing β-cells of the pancreatic islets, which
thus models type 1 diabetes resulted from an auto immune-
mediated loss of β-cell mass.(30) Hyperglycemia induced by
streptozotocin exaggerates LV remodeling and failure after
MI.(31,32) In contrast, type 2 diabetes is typically preceded by
obesity and associated metabolic abnormalities such as insulin
resistance and dyslipidemia. Type 2 diabetes can be modeled by
feeding a high-fat diet (HFD) in mice.(33) A HFD leads to insulin
resistance, impaired glucose tolerance, an increase in body fat
and dyslipidemia, and eventually fasting hyperglycemia. We
demonstrated that HFD induced type 2 diabetes characterized
by insulin resistance and obesity in mice and exacerbated LV
remodeling and failure after MI.(34) Similarly, in Goto Kakizaki
rats, a nonobese type 2 diabetes model, the progression of HF was
accelerated after MI.(35) Therefore, either type 1 or type 2 diabetes
exaggerates post-MI LV remodeling and failure.
The production of ROS is increased in post-MI hearts, and
pharmacological and genetic interventions to scavenge ROS can
ameliorate this disease process.(36,37) Importantly, the activation
of NAD(P)H oxidase enhances oxidative stress and plays an
important role also in the progression of post-MI diabetic heart(34)
as in other diabetic complications.(38–40)
Skeletal Muscle Dysfunction in Diabetes Mellitus
In patients with type 2 diabetes, the exercise capacity is limited(41)
and the lower exercise capacity is a significant independent
predictor for mortality.(42) Exercise intolerance is generally
believed to be due to the abnormalities in the energy metabolism
in skeletal muscle.(43) Moreover, mitochondrial fatty acid β-
oxidation and mitochondrial respiration were impaired in skeletal
muscle from patients with type 2 diabetes.(44) These results suggest
that diabetes may adversely affect mitochondrial function in
skeletal muscle and lead to exercise intolerance. However, the
pathogenesis of skeletal muscle dysfunction in type 2 diabetes
remains undefined. Systemic oxidative stress has been reported
to be increased in type 2 diabetes.(45) Moreover, the mitochondrial
structure and function were impaired in skeletal muscle from
HFD-fed rodents with the altered oxidative stress markers.(46–48)
Therefore, increased oxidative stress in skeletal muscle may
impair mitochondrial function and limit the exercise capacity in
type 2 diabetes.
We demonstrated that the exercise capacity was limited in the
diabetic mice induced by HFD feeding.(49) This limitation of
maximal exercise capacity was accompanied by a decrease of
peak  VO2. Coincident with these alterations, mitochondrial
respiratory activity, electron transport chain (ETC) complex I
and III activities and skeletal muscle mitochondrial content were
decreased in the HFD mice. These findings are supported by the
previous studies in patients with insulin resistance or type 2
diabetes, in which mitochondrial ATP production and state 3
respiration were decreased in skeletal muscle.(44) Moreover, mito-
chondrial oxidative phosphorylation genes including ubiquinol
cytochrome c reductase binding protein, a subunit of complex III,
were downregulated in skeletal muscle from patients with
diabetes, and their expression levels were positively correlated
with peak VO2.(50) Accordingly, the metabolic abnormalities in the
mitochondria from skeletal muscle can well explain a decrease in
the exercise capacity and peak VO2 in the diabetic mice.
Importantly, chronic administration of apocynin in the HFD
mice significantly ameliorated the limited exercise capacity as
well as mitochondrial dysfunction in skeletal muscle without
affecting glucose metabolism or body fat. Therefore, increased
oxidative stress causes mitochondrial dysfunction in skeletal
muscle and contribute to exercise intolerance in diabetes. These
findings are in agreement with our previous study that the exercise
capacity was reduced in conditions in which O2￿− was increased
in heterozygous manganese SOD gene knockout mice.(51) The
exercise capacity has been reported to be decreased also in rats
fed vitamin E-deficient diets.(52) Therefore, oxidative stress and
mitochondrial dysfunction in skeletal muscle play a crucial role
not only in the development of insulin resistance but also exercise
intolerance in type 2 diabetes.
The decrease of mitochondrial ETC complex I and III activities
can potentially be explained by direct oxidative damage to mito-
chondrial complexes.(53) Mitochondria can be the primary target
for oxidative damage when ROS production exceeds the capacity
of the endogenous ROS scavenging system. O2￿− can easily impair
these ETC complexes because they include iron-sulfur center.(54)
In addition, oxidative damage to mitochondrial DNA can also
result in the decrease in ETC complex activities.(55) Furthermore,
the impaired mitochondrial DNA may adversely affect mito-
chondrial biogenesis.
An explosive increase of patients with type 2 diabetes is a
growing medical as well as public health problem in industrialized
countries. Therefore, the development of novel therapeutic
approaches for diabetes is an important goal for further investiga-
tion. The first line in the prevention and treatment of diabetes is
the lifestyle modification including diet and physical exercise.
Exercise training can increase mitochondrial oxidative capacity in
skeletal muscle and delay or prevent diabetes by increasing insulin
sensitivity. However, the limited exercise capacity might prevent
the completion of proper exercise in patients with type 2 diabetes.
Therefore, therapies designed to regulate oxidative stress and
maintain mitochondrial function in skeletal muscle are expected
to increase the exercise capacity, which may be beneficial in
the treatment of diabetes and the prevention of cardiovascular
diseases.
Conclusion
To improve the outcomes of patients with HF, the development
of therapeutic strategies based on a novel insight into the patho-
physiology of cardiac and skeletal muscle remodeling is critically
needed.(56–58) Therapies designed to interfere with oxidative stress
could be beneficial to prevent not only diabetic heart disease but
also skeletal muscle dysfunction in diabetes.
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